Reading Time: 6 minutesMND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains
Category: Markers of Disease Progression
Reading Time: 5 minutesResearch into MND has increased over recent years and we now have a greater understanding of what is happening within the body during the disease.
Reading Time: 4 minutesA recent paper published in Brain Communications has identified several lipid (fat-like) molecules that are elevated in MND, specifically amyotrophic lateral sclerosis (ALS) which is
Reading Time: 5 minutesWhat is a clinical endpoint?
A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.
To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.
Reading Time: 6 minutesA recent paper (October 2022), published in the journal Journal of Pathology: Clinical Research suggests that evidence of MND can be seen inside people years before
Reading Time: 2 minutesHello, my name is Judith Bilgorai and I am a first year PhD student, funded by the MND Association, at King’s College London. I work
Reading Time: 5 minutesEach year, the 21st of June marks Global MND Awareness Day and MND Charites and Associations across the world acknowledge the impact that MND has
Reading Time: 6 minutesMy name is Stephanie Shepheard, and I am a Research Associate in the Motor Neuron Disease & Neurotrophic Research Laboratory (MND&NR Lab), Flinders Health &
Reading Time: 4 minutesDiagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that